Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Vaccine efficacy against VMCCI, CCI, and LCI in the Per-Protocol analyses.

From: Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

  Season 1
2005-2006
Season 2
2006-2007
Overall Overall efficacy (97.5% CI lower bound)
  Vaccine
N = 1706
n (%)
Placebo
N = 1725
n (%)
Vaccine
N = 2011
n (%)
Placebo
N = 2043
n (%)
Vaccine
N = 3714
n (%)
Placebo
N = 3768
n (%)
 
VMCCI 14 (0.8) 30 (1.7) 9 (0.4) 15 (0.7) 23 (0.6) 45 (1.2) 46.3% (9.8%)
CCI 19 (1.1) 38 (2.2) 11 (0.5) 22 (1.1) 30 (0.8) 60 (1.6) 49.4% (20.3%)
LCI 24 (1.4) 69 (4.0) 20 (1.0) 53 (2.6) 44 (1.2) 122 (3.2) 63.2% (48.2%)
  1. VMCCI, culture-confirmed influenza A and B matching vaccine; CCI, any culture-confirmed influenza A and B; LCI, any culture- or serology-confirmed influenza A or B; CI, Confidence Interval